562 related articles for article (PubMed ID: 31632401)
1. Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide.
Greco R; Lorentino F; Nitti R; Lupo Stanghellini MT; Giglio F; Clerici D; Xue E; Lazzari L; Piemontese S; Mastaglio S; Assanelli A; Marktel S; Corti C; Bernardi M; Ciceri F; Peccatori J
Front Immunol; 2019; 10():2319. PubMed ID: 31632401
[No Abstract] [Full Text] [Related]
2. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
3. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
[TBL] [Abstract][Full Text] [Related]
4. Elafin as a Predictive Biomarker of Acute Skin Graft-
Solán L; Carbonell D; Muñiz P; Dorado N; Landete E; Chicano-Lavilla M; Anguita J; Gayoso J; Kwon M; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2021; 12():516078. PubMed ID: 33679728
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
[TBL] [Abstract][Full Text] [Related]
6. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
7. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
8. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
11. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
[TBL] [Abstract][Full Text] [Related]
12. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
13. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2019; 10():2338. PubMed ID: 31649665
[TBL] [Abstract][Full Text] [Related]
14. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
[TBL] [Abstract][Full Text] [Related]
16. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
[No Abstract] [Full Text] [Related]
17. Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro J; Roldán E; Piñana JL; Barba P; Chorão P; Quintero A; Hernani R; Ortí G; Lorenzo JI; Balaguer-Roselló A; Salamero O; Fox L; Solves P; Gómez I; Guerreiro M; Hernández Boluda JC; Sanz G; Solano C; Sanz MÁ; Valcárcel D; Sanz J
Eur J Haematol; 2021 Jan; 106(1):114-125. PubMed ID: 33025625
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.
Kwon M; Bailén R; Pascual-Cascón MJ; Gallardo-Morillo AI; García Sola A; Balsalobre P; Solán L; Dorado N; Muñoz C; Serrano D; Martínez-Laperche C; Buño I; Anguita J; Díez-Martin JL
Blood Adv; 2019 Nov; 3(21):3351-3359. PubMed ID: 31698447
[TBL] [Abstract][Full Text] [Related]
19. Changes in protein serum levels during stem cell transplantation.
Metafuni E; Giammarco S; De Ritis DG; Rossi M; Corrente F; Piccirillo N; Bacigalupo AP; Sica S; Chiusolo P
Eur J Clin Invest; 2017 Oct; 47(10):711-718. PubMed ID: 28796281
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
